Optimizing Periprocedural Antiplatelet Therapy: Clinical Outcomes Of Intravenous Versus Oral P2y12 Inhibitors In Neurovascular and Cardiovascular Interventions (AAN 2026) - Mar 6, 2026 - Abstract #008; Pres time: Apr 20, 2026; 04:54 PM - 05:06 PM; Location: McCormick Place West | W190a; In-Person; Virtual; "Objective To evaluate whether intravenous (IV) cangrelor offers clinical advantages over oral P2Y12 inhibitors (ticagrelor, prasugrel) in periprocedural antiplatelet therapy during cardiovascular and neurovascular interventions. A unified IV protocol combining thrombolysis (e.g., tenecteplase) and antiplatelet therapy (e.g., cangrelor) may streamline emergent care. Multicenter RCTs are warranted to define optimal strategies for both cardiovascular and neurovascular interventions."
Clinical • Clinical data • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Myocardial Infarction • Thrombosis
|
|
Wesley Julius1; Syed Naqvi1
|